BTL Industries’ Emface Wins FDA Nod for TMJ Dysfunction

BTL Industries has expanded the U.S. Food and Drug Administration (FDA)-cleared applications of its Emface platform with a new indication to treat temporomandibular joint (TMJ) dysfunction.

Emface is now authorized for relief of symptoms associated with muscle spasm, treatment of TMJ dysfunction and associated pain, muscle re-education, increased local blood flow, and the maintenance or improvement of mandibular range of motion.

The technology combines synchronized radiofrequency (RF) and the company’s HIFES tech to stimulate facial muscles. This can provide relief without surgery, injections, or medication.

“EMFACE is an established technology platform with multiple FDA-cleared uses,” said David Chmel, CEO of BTL Industries. “This new indication allows dental, oral health, and wellness providers to address TMJ dysfunction within its approved uses, expanding the benefits of EMFACE to more patients.”

“TMJ dysfunction impacts more than the jaw—it affects quality of life,” added Shireen Dhanani, DMD, Leesburg, Fla. “With EMFACE, we can now offer an accessible, non-invasive option that not only helps patients find relief and functional improvement, but also expands the scope of dental care.”

BTL was founded in 1993 and offers solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more.